NGM Biopharmaceuticals In... (NGM)
NASDAQ: NGM
· Real-Time Price · USD
1.54
-0.02 (-1.28%)
At close: Apr 03, 2024, 3:59 PM
NGM Biopharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 165K | 582K | 1.42M | 2.25M | 18.18M | 7.91M | 8.29M | 20.95M | 20.96M | 18.57M | 16.77M | 21.57M |
Cost of Revenue | 518K | 500K | 1.12M | 1.12M | 1.11M | 1.09M | 1.4M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -353K | 82K | 304K | 1.13M | 17.07M | 6.82M | 6.89M | 20.95M | 20.96M | 18.57M | 16.77M | 21.57M |
Operating Income | -29.66M | -31.03M | -40.58M | -50.19M | -38.3M | -48.3M | -47.07M | -32.58M | -27.22M | -29.01M | -36.62M | -27.84M |
Interest Income | 2.04M | 2.25M | 2.45M | 2.58M | 2.03M | 965K | 543K | 176K | 85K | 106K | 115K | 114K |
Pretax Income | -27.67M | -28.8M | -38.26M | -47.65M | -36.44M | -47.26M | -46.52M | -32.45M | -27.23M | -28.86M | -36.69M | -27.54M |
Net Income | -27.67M | -28.8M | -38.26M | -45.1M | -34.58M | -46.22M | -45.97M | -32.32M | -27.23M | -28.86M | -36.69M | -27.54M |
Selling & General & Admin | 7.94M | 8.67M | 9.65M | 11.58M | 9.76M | 10.11M | 9.93M | 10.72M | 9.45M | 8.87M | 9.82M | 8.72M |
Research & Development | 21.37M | 22.94M | 32.35M | 40.86M | 46.72M | 46.11M | 45.43M | 42.81M | 38.73M | 38.71M | 43.57M | 40.7M |
Other Expenses | -48K | -15K | -134K | -37K | -170K | 78K | 5K | -45K | -95K | 35K | -187K | 187K |
Operating Expenses | 29.31M | 31.61M | 42M | 52.44M | 56.48M | 56.22M | 55.36M | 53.53M | 48.18M | 47.58M | 53.39M | 49.42M |
Interest Expense | 2.55M | n/a | n/a | n/a | 2.03M | 965K | 543K | 176K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 29.83M | 31.61M | 42M | 52.44M | 56.48M | 56.22M | 55.36M | 53.53M | 48.18M | 47.58M | 53.39M | 49.42M |
Income Tax Expense | n/a | n/a | n/a | -2.55M | -1.86M | -1.04M | -548K | -131K | n/a | -106K | -115K | -114K |
Shares Outstanding (Basic) | 82.8M | 82.71M | 82.46M | 82.01M | 81.79M | 80.62M | 79.27M | 78.02M | 77.78M | 77.41M | 77.1M | 76.03M |
Shares Outstanding (Diluted) | 82.8M | 82.71M | 82.46M | 82.01M | 81.79M | 80.62M | 79.27M | 78.02M | 77.78M | 77.41M | 77.1M | 76.03M |
EPS (Basic) | -0.33 | -0.35 | -0.46 | -0.55 | -0.42 | -0.57 | -0.58 | -0.41 | -0.35 | -0.37 | -0.48 | -0.36 |
EPS (Diluted) | -0.33 | -0.35 | -0.46 | -0.55 | -0.42 | -0.57 | -0.58 | -0.41 | -0.35 | -0.37 | -0.48 | -0.36 |
EBITDA | -29.14M | -30.5M | -40.02M | -50.19M | -38.3M | -47.71M | -45.67M | -31.15M | -27.22M | -27.51M | -35.06M | -26.29M |
EBIT | -25.12M | -31.03M | -40.58M | n/a | -34.41M | -46.3M | -45.98M | -32.27M | n/a | -29.01M | -36.62M | -27.84M |
Depreciation & Amortization | 518K | 535K | 559K | 609K | 614K | 598K | 1.4M | 1.43M | 1.48M | 1.49M | 1.56M | 1.55M |